Deals Of The Week: Big Pharmas Hoard Cash, But Aren’t Buying Yet In 2013

DOTW digs into a Moody’s report detailing which companies’ balance sheets have the most cash, even if the pharmas that made the cut haven’t been putting their purchasing power to work. In addition, details on Valeant’s latest dermatology acquisition, Merck’s deal with Cerecor for a portfolio of COMT assets, Janssen’s European cancer research tie-up, and an NPS/Takeda deal for orphan drugs.